These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36581339)

  • 21. Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina.
    Semiz S; Dujić T; Ostanek B; Prnjavorac B; Bego T; Malenica M; Mlinar B; Marc J; Causević A
    Med Glas (Zenica); 2011 Feb; 8(1):84-9. PubMed ID: 21263403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
    Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
    J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients.
    Monostory K; Tóth K; Kiss Á; Háfra E; Csikány N; Paulik J; Sárváry E; Kóbori L
    Br J Clin Pharmacol; 2015 Dec; 80(6):1429-37. PubMed ID: 26271661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP3A genotypes of donors but not those of the patients increase the risk of acute rejection in renal transplant recipients on calcineurin inhibitors: a pilot study.
    Gervasini G; García-Pino G; Vergara E; Mota-Zamorano S; García-Cerrada M; Luna E
    Eur J Clin Pharmacol; 2018 Jan; 74(1):53-60. PubMed ID: 29043387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant.
    Hannachi I; Ben Fredj N; Chadli Z; Ben Fadhel N; Ben Romdhane H; Touitou Y; Boughattas NA; Chaabane A; Aouam K
    Toxicol Appl Pharmacol; 2020 Jun; 396():115000. PubMed ID: 32275916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of CYP3A4*1B genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: A meta-analysis.
    Wang CE; Lu KP; Chang Z; Guo ML; Qiao HL
    Gene; 2018 Jul; 664():44-49. PubMed ID: 29678659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. UHPLC-MS/MS method for determination of atorvastatin calcium in human plasma: Application to a pharmacokinetic study based on healthy volunteers with specific genotype.
    Xia B; Li Y; Zhang Y; Xue M; Li X; Xu P; Xia T; Chen S
    J Pharm Biomed Anal; 2018 Oct; 160():428-435. PubMed ID: 30130726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation.
    Bouamar R; Hesselink DA; van Schaik RH; Weimar W; Macphee IA; de Fijter JW; van Gelder T
    Ther Drug Monit; 2011 Apr; 33(2):178-84. PubMed ID: 21383650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant.
    Sweiss K; Vemu B; Hofmeister CC; Wenzler E; Calip GS; Galvin JP; Mahmud N; Rondelli D; Johnson JJ; Patel P
    Br J Clin Pharmacol; 2020 Nov; 86(11):2165-2173. PubMed ID: 32285957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases.
    Jin M; Gock SB; Jannetto PJ; Jentzen JM; Wong SH
    J Anal Toxicol; 2005 Oct; 29(7):590-8. PubMed ID: 16419387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
    Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
    Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
    Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T
    Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition.
    Yin OQ; Tomlinson B; Chow MS
    J Clin Pharmacol; 2010 Oct; 50(10):1136-41. PubMed ID: 20133509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
    Pai AA; Devasia AJ; Panetta JC; Mani S; Stallon Illangeswaran RS; Mohanan E; Balakrishnan B; Lakshmi KM; Kulkarni U; Aboobacker FN; Korula A; Abraham A; Srivastava A; Mathews V; George B; Balasubramanian P
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):130-135.e1. PubMed ID: 31791694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients.
    Miura M; Satoh S; Kagaya H; Saito M; Numakura K; Tsuchiya N; Habuchi T
    Pharmacogenomics; 2011 Jul; 12(7):977-84. PubMed ID: 21635144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients.
    Moes DJ; van der Bent SA; Swen JJ; van der Straaten T; Inderson A; Olofsen E; Verspaget HW; Guchelaar HJ; den Hartigh J; van Hoek B
    Eur J Clin Pharmacol; 2016 Feb; 72(2):163-74. PubMed ID: 26521259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients.
    Qiu F; He XJ; Sun YX; Li-Ling J; Zhao LM
    Pharmacol Rep; 2011; 63(3):815-25. PubMed ID: 21857093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose.
    Dally H; Edler L; Jäger B; Schmezer P; Spiegelhalder B; Dienemann H; Drings P; Schulz V; Kayser K; Bartsch H; Risch A
    Pharmacogenetics; 2003 Oct; 13(10):607-18. PubMed ID: 14515059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Genetic Polymorphism in CYP3A4 and CYP3A5 Genes on Tacrolimus Dose Among Kidney Transplant Recipients.
    Yousef AM; Qosa H; Bulatova N; Abuhaliema A; Almadhoun H; Khayyat G; Olemat M
    Iran J Kidney Dis; 2016 May; 10(3):156-63. PubMed ID: 27225724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.